The Radboud Biobank Oncology stores biomaterial (plasma, serum, cfDNA, tumor tissue) from patients with a proven malignancy or a high suspicion of malignancy, together with data about the patient's disease course. The biobank aims to contribute to research in the field of diagnosis, prognosis, a deeper understanding of the disease process and to the development of more efficient therapies. By joining forces at the Radboudumc, a unique project has been created that can provide a strong stimulus to scientific oncological research at the Radboudumc.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
New Automated PBMC isolation method introduced in LMI.21 September 2021
The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.read more
Lysine Metabolism sub-biobank21 September 2021
Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.read more